Pfizer: Phase 3 Trial Of Investigational C. Difficile Vaccin

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said Tuesday that the CLOVER trial, a pivotal Phase 3 study evaluating its Clostridioides difficile vaccine candidate (PF-06425090) in the prevention

Related Keywords

, Pfizer , Pfizer Inc , Drug Administration , Hase , Trial , Investigational , Difficile , Vaccine , Nails , Feet , Primary , Goal ,